The TRISCEND II Trial: Practice-Changing Implications

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Equity/Stock(s)/Options - Dura Biotech; Thubrikar Aortic Valve Inc; MicroInterventional Devices; Supira; Admedus; TriFlo; Adona; Tioga</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Philips; Admedus; TriCares; Dura BioTech</li><li>Grant Support/Research Contract - Edwards Lifesciences; Abbott; Medtronic; Boston Scientific Corporation; JenaValve</li></ul>